Significantly lower risks seen for those receiving GLP-1 receptor agonists compared with other antidiabetic drugs.

A recent study found that tumors in mice shrank after they were administered tirzepatide. It could take years for GLP-1 drugs to obtain regulatory approval as cancer-related treatments.

As more research is done on GLP-1 drugs, the number of indications they can treat may grow significantly. And if tirzepatide is able to help treat cancer, it could make this already massive drug a ...

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who had been on GLP-1 medications for a year.

No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA vs DPP4i users.

The demand for GLP-1 medications is only increasing. As employees seek better health benefits, employers who act now will set themselves apart in a competitive job market.

THURSDAY, July 24, 2025 (HealthDay News) -- For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause ...

GLP-1 Drugs May Cause Dehydration, Experts Say, Especially In Extreme Heat The hunger-reducing mechanisms of GLP-1 drugs, as well as their side effects, may contribute to dehydration.

Experts say people who take GLP-1 weight loss medications should stay hydrated, particularly when temperatures are high. The hunger-reducing mechanisms of GLP-1 drugs, as well as their side ...

FDA mandates GLP-1 drug label updates for kidney injury risk due to dehydration, urging caution for users with gastrointestinal issues.

New research from experts at the University of Virginia (UVA) says that GLP-1 drugs may help people lose weight, but do not provide benefits that set the body up for long-term good health.

Patients with idiopathic intracranial hypertension who use a GLP-1 receptor agonist are less likely to experience symptoms, require medications, or undergo surgery.